Exhibit 10.1

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

Second Amendment to Product Agreement

between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.

 

This Second Amendment to Product Agreement (the “Amendment”), dated October 6,
2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc.
(“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).  

 

WHEREAS, Patheon and ACADIA have entered into that certain Master Manufacturing
Services Agreement, dated August 3, 2015 (the “MSA”) and that certain Product
Agreement under the MSA, dated August 3, 2015, as amended on April 25, 2016 (the
“Product Agreement”); and

 

WHEREAS, Patheon and ACADIA now wish to amend the Product Agreement as set forth
in this Amendment.  All capitalized terms used but not defined in this Amendment
shall have the respective meanings set forth in the MSA or Product Agreement, as
applicable.

 

NOW THEREFORE in consideration of the premises hereof and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged by the parties, the parties agree as follows:

 

1.Amendment to Schedule C.  The stability pricing table on Schedule C of the
Product Agreement is hereby amended and replaced with the stability pricing
tables set forth on Exhibit 1 of this Amendment.  

  

2.Side Letter Agreements.  The parties hereby agree that any future changes to
stability testing set forth in Schedule C of the Product Agreement, and any
annual adjustments to Product pricing set forth in Schedule B of the Product
Agreement pursuant to Section 4.2 of the MSA, may be documented via separate
side letter agreement between Patheon and ACADIA.

 

3.No Other Modifications. Except as specifically modified by this Amendment, the
terms and conditions of the Product Agreement including, without limitation, all
other terms and conditions included in each of the amended Schedules, and the
MSA, shall remain unchanged.

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed
by their authorized representatives, effective as of the Amendment Date.

 

Patheon Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.  

 

 

By: /s/ Nicholas M. BuschurBy: /s/ James Nash

 

Name:  Nicholas M. BuschurName:  James Nash

 

 

--------------------------------------------------------------------------------

 

Title:  Executive Director & GM

Title:   SVP, Technology Development &

Operations    

 

Exhibit 1

 

Updated Stability Pricing

 

[…***…]

 

2

 

--------------------------------------------------------------------------------

 

[…***…]

 

3

 

--------------------------------------------------------------------------------

 

[…***…]

4

 

--------------------------------------------------------------------------------

 

[…***…]

5

 

--------------------------------------------------------------------------------

 

[…***…]

6